Lena Brandefors

Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial

Magnus Tobiasson, I Dybedahl, Mette Skov Holm et al. · Blood Cancer Journal · 2014 · 55 citations · Full text

Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia

Christian Buske, Meletios Α. Dimopoulos, Alexander Grunenberg et al. · Journal of Clinical Oncology · 2023 · 36 citations

Prognostic factors and primary treatment for Waldenström macroglobulinemia – a Swedish Lymphoma Registry study

Lena Brandefors, Beatrice Melin, Jack Lindh et al. · British Journal of Haematology · 2018 · 16 citations · Full text

Bortezomib in Combination with Dexamethasone, Rituximab and Cyclophosphamide (B-DRC) As First - Line Treatment of Waldenstrom's Macroglobulinemia: Results of a Prospectively Randomized Multicenter European Phase II Trial

Christian Buske, Meletios Α. Dimopoulos, Alexander Grunenberg et al. · Blood · 2020 · 16 citations

Familial Waldenstrom’s macroglobulinemia and relation to immune defects, autoimmune diseases, and haematological malignancies – A population-based study from northern Sweden

Lena Brandefors, Eva Kimby, Lundqvist Kristina et al. · Acta Oncologica · 2015 · 14 citations · Full text